Microcap Ledger Nautilus Biotechnology, Inc. $NAUT
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Laboratory Analytical Instruments
- Headquarters
- Seattle, WA
- Fiscal year end
- December 31
- Shares outstanding
- 127,255,223 [10-Q 2026-07-28]
What the company doesAI summary of filing
Nautilus Biotechnology is a development-stage life sciences company that develops the Nautilus Voyager platform, a proteomics measurement system designed to identify and quantify proteins and their functional variants, called proteoforms, in biological samples. The company is pre-revenue and currently operates an Early Access Program launched in January 2026 that provides proteomics analysis services to select customers, with a longer-term strategy to commercialize instruments, consumables, and software for broader market adoption. Nautilus makes money through fee-for-service proteomics analysis under its early access program, with plans to generate future revenue from instrument sales and accompanying recurring revenue from consumables, services, and software. [10-K 2026-02-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $190.0K | −$29.17M | −$26.83M | $13.17M | [10-Q 2026-07-28] |
| FY ended Dec 2025 | — | −$59.00M | −$50.70M | $12.39M | [10-K 2026-02-26] |
| FY ended Dec 2024 | — | −$70.78M | −$59.15M | $27.65M | [10-K 2026-02-26] |
- Quarterly cash burn
- −$13.41M
- Cash runway Estimate
- ~2.9 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-24 | 125,563,965 | [10-Q 2024-10-29] |
| 2025-02-21 | 126,148,469 | [10-K 2025-02-27] |
| 2025-04-24 | 126,148,469 | [10-Q 2025-04-29] |
| 2025-07-25 | 126,305,122 | [10-Q 2025-07-31] |
| 2025-10-23 | 126,305,122 | [10-Q 2025-10-28] |
| 2026-02-19 | 126,564,473 | [10-K 2026-02-26] |
| 2026-04-23 | 127,078,855 | [10-Q 2026-04-28] |
| 2026-07-24 | 127,255,223 | [10-Q 2026-07-28] |
- Shelf registration
- S-3 filed 2026-09-11; declared effective 2026-09-18 [S-3 2026-09-11]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-05-02. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-05-02 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-02] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-02 | Ah Equity Partners Bio Ii, L.L.C. | sell | 4,615,974 | $2.35 | [4 2026-06-04] |
| 2026-06-02 | Ah Equity Partners Bio Ii, L.L.C. | sell | 384,026 | $2.35 | [4 2026-06-04] |
| 2026-03-04 | Patel Sujal M | buy | 25,000 | $2.61 | [4 2026-03-04] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-18 | 424B5 | Prospectus or prospectus supplement |
| 2026-09-11 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-09-11 | 8-K | Material agreement entered; Material agreement terminated |
| 2026-09-11 | S-3 | Registration statement |
| 2026-08-28 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-07-28 | 10-Q | Quarterly report |
| 2026-07-28 | 8-K | Results of operations |
| 2026-06-30 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-06-18 | 8-K | Shareholder vote results |
| 2026-06-04 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-04-28 | DEF 14A | Proxy statement |
Alerts for $NAUT
Email me when Nautilus Biotechnology, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.